Related Experiment Video
Updated: Nov 1, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Peritumoral Microgel Reservoir for Long-Term Light-Controlled Triple-Synergistic Treatment of Osteosarcoma with
Jiaqi Yan1,2,3, Yichuan Wang4, Meixin Ran1,2,3
1Department of Radiology, Shanghai Institute of Traumatology and Orthopaedics, RuiJin Hospital LuWan Branch, Shanghai Jiao Tong University School of Medicine, 149 ChongqingNan Road, Shanghai, 200020, P. R. China.
Abstract:
Local minimally invasive injection of anticancer therapies is a compelling approach to maximize the utilization of drugs and reduce the systemic adverse drug effects. However, the clinical translation is still hampered by many challenges such as short residence time of therapeutic agents and the difficulty in achieving multi-modulation combination therapy. Herein, mesoporous silica-coated gold nanorods (AuNR@SiO2 ) core-shell nanoparticles are fabricated to facilitate drug loading while rendering them photothermally responsive. Subsequently, AuNR@SiO2 is anchored into a monodisperse photocrosslinkable gelatin (GelMA) microgel through one-step microfluidic technology. Chemotherapeutic drug doxorubicin (DOX) is loaded into AuNR@SiO2 and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is loaded in the microgel layer. The osteosarcoma targeting ligand alendronate is conjugated to AuNR@SiO2 to improve the tumor targeting. The microgel greatly improves the injectability since they can be dispersed in buffer and the injectability and degradability are adjustable by microfluidics during the fabrication. The drug release can, in turn, be modulated by multi-round light-trigger. Importantly, a single super low drug dose (1 mg kg-1 DOX with 5 mg kg-1 DMXAA) with peritumoral injection generates long-term therapeutic effect and significantly inhibited tumor growth in osteosarcoma bearing mice. Therefore, this nanocomposite@microgel system can act as a peritumoral reservoir for long-term effective osteosarcoma treatment.
Insights
This study developed a novel nanocomposite microgel system for localized osteosarcoma treatment. The system effectively delivers low doses of chemotherapy drugs, showing significant long-term tumor inhibition in mice.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Cancer Therapy
Background:
- Local minimally invasive anticancer therapies offer advantages but face challenges like short drug residence time and difficulty in combination therapy.
- Developing advanced drug delivery systems is crucial for effective cancer treatment with reduced side effects.
Purpose of the Study:
- To fabricate a mesoporous silica-coated gold nanorod (AuNR@SiO2) and gelatin methacryloyl (GelMA) microgel nanocomposite for localized osteosarcoma treatment.
- To achieve controlled, long-term release of combined chemotherapeutics (doxorubicin and DMXAA) and enhance tumor targeting.
Main Methods:
- Fabrication of AuNR@SiO2 nanoparticles for drug loading and photothermal response.
- Integration of AuNR@SiO2 into GelMA microgels using microfluidic technology.
- Loading doxorubicin (DOX) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) into the system, and conjugating alendronate for targeting.
Main Results:
- The developed microgel system demonstrated improved injectability and tunable degradability.
- Multi-round light-triggered drug release was achieved, with a single low-dose injection showing long-term therapeutic effects.
- Significant inhibition of tumor growth was observed in osteosarcoma-bearing mice.
Conclusions:
- The nanocomposite@microgel system serves as an effective peritumoral reservoir for sustained osteosarcoma treatment.
- This approach minimizes systemic toxicity by maximizing local drug utilization.
- The study highlights the potential of advanced nanomaterials and microgels in localized cancer therapy.
More Related Videos
06:02Multi-timescale Microscopy Methods for the Characterization of Fluorescently-labeled Microbubbles for Ultrasound-Triggered Drug Release
Published on: June 12, 2021
04:25Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021